Breathe BioMedical Inc. is a medical technology company. It is focused on developing a breath test to be used as an adjunctive test to mammography screening to detect early-stage breast cancer in women with dense breast tissue. Breath analytics involves the collection, processing, and analysis of breath samples to identify biomarker patterns associated with specific diseases. It is developing a proprietary end-to-end breath analytics platform, the intended use of which is to enable breath testing for the detection of disease. Its platform technology combines three advanced technologies to sample, digitize and analyze breath with the potential to detect multiple diseases. Its spectrometer technology uses Cavity Ring-Down Spectroscopy (CRDS) to measure the volatile organic compounds (VOCs) in breath samples which are collected using its breath sampler device (SohnoXB). Spectrometer is designed to be very fast, permitting sample analysis down to parts-per-trillion levels.
公司代碼BRTH
公司Breathe BioMedical Ord Shs (Proposed)
CEODawes (William)
網址https://breathebiomedical.com/
常見問題
Breathe BioMedical Ord Shs (Proposed)(BRTH)的當前股價是多少?
Breathe BioMedical Ord Shs (Proposed)(BRTH)的當前股價是 --。
Breathe BioMedical Ord Shs (Proposed) 的股票代碼是什麼?
Breathe BioMedical Ord Shs (Proposed)的股票代碼是BRTH。
Breathe BioMedical Ord Shs (Proposed)股票的52週最高點是多少?
Breathe BioMedical Ord Shs (Proposed)股票的52週最高點是--。
Breathe BioMedical Ord Shs (Proposed)股票的52週最低點是多少?
Breathe BioMedical Ord Shs (Proposed)股票的52週最低點是--。
Breathe BioMedical Ord Shs (Proposed)的市值是多少?
Breathe BioMedical Ord Shs (Proposed)的市值是--。
Breathe BioMedical Ord Shs (Proposed)的淨利潤是多少?
Breathe BioMedical Ord Shs (Proposed)的淨利潤為--。
現在Breathe BioMedical Ord Shs (Proposed)(BRTH)的股票是買入、持有還是賣出?
根據分析師評級,Breathe BioMedical Ord Shs (Proposed)(BRTH)的總體評級為--,目標價格為--。
Breathe BioMedical Ord Shs (Proposed)(BRTH)股票的每股收益(EPS TTM)是多少
Breathe BioMedical Ord Shs (Proposed)(BRTH)股票的每股收益(EPS TTM)是--。